BX Swiss TOP 30 CHF
1.364,30
PKT
+4,19
PKT
+0,31
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 08.02.05 | UBS Outperform | Credit Suisse First Boston | |
| 09.02.05 | UBS Overweight | Lehman Brothers | |
| 08.02.05 | Zurich Insurance Buy | Sarasin Research | |
| 07.02.05 | ABB (Asea Brown Boveri) Kaufen | Helaba Trust | |
| 08.02.05 | Adecco SA Neutral | Sarasin Research | |
| 08.02.05 | UBS Overweight | JP Morgan | |
| 07.02.05 | UBS Overweight | JP Morgan | |
| 07.02.05 | Swiss Life Marketperformer | LB Rheinland-Pfalz | |
| 07.02.05 | ABB (Asea Brown Boveri) Neutral | Sarasin Research | |
| 07.02.05 | Roche Buy | Sarasin Research | |
| 07.02.05 | UBS Halten | Helaba Trust | |
| 03.03.05 | Givaudan Neutral | Sarasin Research | |
| 03.02.05 | Roche In-Line | Goldman Sachs | |
| 07.02.05 | UBS Buy | SEB | |
| 03.02.05 | Zurich Insurance Neutral | JP Morgan | |
| 03.02.05 | Swiss Life Outperform | HypoVereinsbank | |
| 03.02.05 | ABB (Asea Brown Boveri) Halten | Helaba Trust | |
| 03.02.05 | Roche Buy | Sarasin Research | |
| 03.02.05 | Swiss Life Sector Outperform | Vontobel | |
| 03.02.05 | Roche Kaufen | LB Baden-Württemberg | |
| 04.02.05 | Swiss Life Outperform | HypoVereinsbank | |
| 03.02.05 | Novartis Übergewichten | Reuschel & Co | |
| 02.02.05 | Roche Buy | Sarasin Research | |
| 02.02.05 | Swiss Life Overweight | JP Morgan | |
| 02.02.05 | Roche Halten | Helaba Trust | |
| 03.02.05 | Roche Buy | Sarasin Research | |
| 01.02.05 | UBS Neutral | Merrill Lynch | |
| 01.02.05 | Novartis Kaufen | SYZ & CO | |
| 01.02.05 | Zurich Insurance Buy | Sarasin Research | |
| 01.02.05 | Roche Halten | Helaba Trust | |
| 01.02.05 | UBS Buy | Merrill Lynch | |
| 01.02.05 | UBS Buy | Sarasin Research | |
| 01.02.05 | Logitech Kauf | SYZ & CO | |
| 01.02.05 | Roche Neutral | Credit Suisse First Boston | |
| 02.02.05 | UBS Outperform | Credit Suisse First Boston | |
| 31.01.05 | Lonza Reduce | Sarasin Research | |
| 31.01.05 | Nestlé Neutral | Sarasin Research | |
| 31.01.05 | Novartis Outperform | Credit Suisse First Boston | |
| 31.01.05 | Roche Buy | Sarasin Research | |
| 28.01.05 | Holcim Verkaufen | Helaba Trust |